Hidroferol

Hidroferol is an oral vitamin D analog containing the active ingredient calcifediol, a 25‑hydroxyvitamin D3 compound. It is marketed in the European Union as an over‑the‑counter product for supplementation. The preparation provides a direct source of calcifediol, which is the circulating form of vitamin D measured to assess status. Hidroferol is intended to support normal calcium and phosphate metabolism when dietary intake or sunlight exposure is insufficient.

Hidroferol is used primarily to correct or prevent low levels of vitamin D in the body, especially when natural synthesis is inadequate. - Treatment of documented vitamin D deficiency in adults. - Prevention of deficiency in individuals with limited sun exposure. - Support of calcium and phosphate balance in patients with osteomalacia risk. - Adjunct supplementation for elderly persons at risk of bone loss. - Management of secondary hyperparathyroidism related to low vitamin D. - Supplementation during pregnancy or lactation when vitamin D requirements are increased, under medical supervision.

Like other vitamin D analogs, Hidroferol may cause adverse reactions, most of which are mild and reversible. Common: - Mild gastrointestinal discomfort such as nausea or abdominal cramps. - Transient headache or dizziness. - Slight increase in serum calcium leading to mild hypercalcemia symptoms (e.g., thirst). - Skin rash or mild itching at the site of irritation. Serious: - Persistent hypercalcemia with symptoms like nausea, vomiting, polyuria, and confusion. - Kidney stones or renal impairment due to elevated calcium levels. - Severe allergic reaction (anaphylaxis) presenting with swelling, difficulty breathing, or hives.

Before using Hidroferol, certain health conditions and circumstances should be considered to minimize risk. - Assess baseline serum calcium and 25‑hydroxyvitamin D levels. - Use caution in patients with a history of hypercalcemia or kidney stones. - Avoid use in individuals with severe renal impairment without medical supervision. - Monitor calcium status during prolonged therapy, especially in the elderly. - Pregnant or breastfeeding women should consult a healthcare professional before starting supplementation. - Concomitant use with high‑dose calcium supplements may increase hypercalcemia risk.

Hidroferol can affect the activity or levels of other substances; some combinations should be avoided, while others require careful monitoring. Avoid: - High‑dose calcium or vitamin D preparations that may cause excess calcium. - Thiazide diuretics, which reduce calcium excretion and increase hypercalcemia risk. - Lithium therapy, which can alter calcium metabolism. - Orlistat, which impairs fat absorption and may reduce calcifediol uptake. Use with caution: - Anticonvulsants such as phenytoin or phenobarbital that increase vitamin D catabolism. - Corticosteroids, which may reduce vitamin D effectiveness. - Bisphosphonates, where combined effects on bone metabolism need monitoring. - Cholestyramine or other bile acid sequestrants that may lower absorption of fat‑soluble vitamins.